Belatacept in Renal Transplantation: Analyses Using Data From the Collaborative Transplant Study (CTS)

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Kidney Transplantation

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT01471223

IM103-089

Details and patient eligibility

About

The purpose of the study is to estimate the incidence rates of Post-transplant Lymphoproliferative Disorder (PTLD), malignancy and hospitalized infections in adult kidney-only transplant recipients treated with Belatacept, and compared the incidences to the incidences in those treated with Calcineurin inhibitor (CNI) based regimens at the time of transplantation.

Full description

Time Perspective: Prospective design, Retrospective data collection and analysis

Enrollment: 89 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 1st kidney only transplant during study, at one of the transplant centers participating in CTS, received Belatacept or a CNI at the time of transplantation

Exclusion criteria

• Patients with a history of malignancy

Trial design

89 participants in 2 patient groups

Patients receiving Belatacept in CTS

Description:

Patients receiving a 1st kidney-only transplant at a center participating in the CTS and receiving Belatacept at the time of transplantation

Patients receiving CNI in CTS

Description:

Patients receiving a 1st kidney-only transplant at a center participating in the CTS and receiving CNI at the time of transplantation